Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2012 1
2019 2
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

4 results
Results by year
Filters applied: . Clear all
Page 1
Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2).
Maher TM, Kreuter M, Lederer DJ, Brown KK, Wuyts W, Verbruggen N, Stutvoet S, Fieuw A, Ford P, Abi-Saab W, Wijsenbeek M. Maher TM, et al. Among authors: stutvoet s. BMJ Open Respir Res. 2019 May 21;6(1):e000422. doi: 10.1136/bmjresp-2019-000422. eCollection 2019. BMJ Open Respir Res. 2019. PMID: 31179008 Free PMC article.
Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors.
Markman B, Tabernero J, Krop I, Shapiro GI, Siu L, Chen LC, Mita M, Melendez Cuero M, Stutvoet S, Birle D, Anak Ö, Hackl W, Baselga J. Markman B, et al. Among authors: stutvoet s. Ann Oncol. 2012 Sep;23(9):2399-2408. doi: 10.1093/annonc/mds011. Epub 2012 Feb 22. Ann Oncol. 2012. PMID: 22357447 Free article. Clinical Trial.